ArticleACS omega2026
Antimalarial Potential of Heme-Targeting Dimeric Compounds: Binding Efficacy vs. Membrane Retention Effects.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria, caused by Plasmodium parasites, remains a major global health burden with high morbidity and mortality rates. Despite the availability of treatments, the therapeutic arsenal is limited, and drug resistance poses a significant challenge. Thus, discovering new antimalarial compounds is critical, and understanding their mechanisms of action is key. One well-studied target is the heme group, which plays a central role in the degradation of the parasite's hemoglobin and infection success. This study describes the dimerization of 3-alkylpyridine derivatives, a class of compounds known to interact with heme, with the aim of enhancing their antimalarial activity. The dimers were analyzed for heme-binding affinity via UV-vis spectroscopy (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.